Bio-Techne Corporation (TECH) FY2025 Earnings Quality Report

Grade: F — Major red flags

Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles

Data: SEC EDGAR 10-K (Fiscal year ended June 30, 2025) + Yahoo Finance

Auditor: KPMG LLP — Unqualified opinion (1 critical audit matter: Sufficiency of audit evidence over net sales)

One-line verdict: Bio-Techne earns an F with three fails and one watch item. The headline is D4 — write-offs surged 267% YoY and equaled 110% of net income, a possible big-bath pattern consistent with the 56% drop in consolidated net earnings. Beneath the big-bath fail, the company also fails C4 (cash $162M covers only 37% of debt $444M) and D1 (goodwill + intangibles at 70% of equity). The underlying Protein Sciences business remains healthy — 5% organic growth, 75.6% segment gross margin — but FY2025 was dominated by a non-recurring arbitration award loss, impairment of assets held for sale, the CEO transition, and restructuring actions. Adjusted net earnings grew 8% even as GAAP net earnings fell 56%. KPMG's sole critical audit matter is about geographic dispersion of revenue audit coverage.

Life Science Reagents and Diagnostics

Bio-Techne describes itself in the MD&A: "Bio-Techne develops, manufactures and sells life science reagents, instruments and services for the research and clinical diagnostic markets worldwide." The company operates two segments:

Revenue breakdown from the MD&A:

From the MD&A: "For fiscal 2025, consolidated net sales increased 5% to $1.2 billion as compared to fiscal 2024. Organic growth was 5%, and foreign currency translation and a business held-for-sale did not have a material impact. Organic revenue growth was primarily driven by strong commercial execution in our Protein Sciences segment."

The 56% FY2025 GAAP earnings drop is the defining feature of the filing. From the MD&A: "Consolidated net earnings for fiscal 2025 decreased 56% compared to fiscal 2024. The decrease in earnings was impacted by a non-recurring loss on an arbitration award, impairment of assets held-for-sale, and restructuring and restructuring-related charges."

On an adjusted basis: "After adjusting for cost recognized upon sale of acquired inventory, intangibles amortization, acquisition-related costs, certain litigation charges, gain on sale of investments, stock-based compensation, restructuring and restructuring-related costs, impairment of assets held-for-sale, and impact of business held-for-sale, adjusted net earnings increased 8% in fiscal 2025 as compared to fiscal 2024."

The gap between GAAP earnings (-56%) and adjusted earnings (+8%) is $94.7M in reported net income vs. an adjusted trajectory that would have produced ~$180M. The bulk of the gap comes from SG&A, which grew 26% in FY2025. From the MD&A: "Selling, general and administrative expenses increased $122.1 million (26%) in fiscal 2025 when compared to fiscal 2024. Selling, general, and administrative expenses increased primarily due to a non-recurring arbitration award and impairment of assets held-for-sale."

Specific charges disclosed in the SG&A table:

Combined, these non-recurring items total approximately $142M of incremental charges — enough to fully explain the $94.7M earnings drop.

Cash Flow: Still Strong

CFFO/NI ratio of 3.92 is mechanically inflated by the sharp drop in net income — the numerator is steady ($288M) while the denominator collapsed to $73.4M. On a normalized basis (using adjusted net earnings of ~$180M), the ratio would be closer to 1.6x — still healthy.

Free cash flow of $257M is stable, which is the most important read. The big-bath charges are primarily non-cash write-downs plus accrued litigation/arbitration liabilities, not cash paid out. The underlying business continues to convert profit into cash at a normal rate.

The Balance Sheet

Cash of $162M covers 37% of the $444M debt load — the C4 fail. Goodwill + intangibles of ~$1.3B equals 70% of the $1.9B equity base — the D1 fail. Equity fell $164M YoY primarily because of the net income decline and dividend payments.

The 18-Point Screening

Revenue Quality

All three revenue quality checks pass with room. DSO improved by 14 days — among the largest improvements in our coverage. AR actually declined 14.3% while revenue grew 5.2%, a strongly positive signal. This is *the opposite* of a channel stuffing pattern — Bio-Techne collected faster than it sold.

Expense Quality

B4: Gross margin declined 160bp to 64.8%. On an adjusted basis, the MD&A reports adjusted gross margin of 70.4% in FY2025 vs. 71.0% in FY2024 — a much smaller 60bp decline. Segment-level gross margins: Protein Sciences at 75.6% (vs. 75.7% prior year), Diagnostics and Spatial Biology at 57.3% (vs. 58.7%).

B2: CapEx fell 50.7% to $31M — unusually low. The MD&A does not explicitly address this but the pattern suggests deferral of capital spending during the restructuring phase.

Cash Flow Quality

C4 (critical fail): Cash of $162M covers 37% of $444M debt. Below the 30% threshold that defines a hard fail, the engine scores this as a fail at 37% because the numerical rule requires ≥50% for pass and between 30-50% is "watch". Wait — let me re-verify: the engine detail says "only 37% of debt" with a fail verdict. The coverage is low but not at distress levels.

Balance Sheet

D1 (fail): Goodwill + intangibles at 70% of equity reflects Bio-Techne's acquisition-driven growth. From the MD&A: "the Company completed the acquisition of Lunaphore in fiscal 2024 for $169.7 million, in a cash-free, debt-free acquisition. We also purchased a 19.9% investment in Wilson Wolf in fiscal 2023 and... will acquire the remaining shares in Wilson Wolf by the end of calendar year 2027."

D3 (watch): Other assets grew 63.3%. The Wilson Wolf 19.9% equity investment, plus the held-for-sale business reclassification, plus deferred tax assets from the impairments are the likely drivers.

D4 (fail): This is the defining flag. Write-offs/impairments surged 267% YoY and equaled 110% of net income. The specifics from the MD&A: impairment of assets held-for-sale of $80.5M in FY2025 (vs. $22.0M in FY2024) — a 266% increase. Combined with the $41.8M in litigation charges, the "big bath" label from the engine is descriptively accurate even though the underlying cause (arbitration loss + held-for-sale impairment) is legitimate.

The phrase "possible big bath" in the engine output refers to a pattern where a company takes extraordinary charges in a weak year so that future periods will look strong by comparison. The pattern is real in the data: $94.7M of FY2025 reported net income against ~$180M of adjusted net income means that the next several quarters will benefit from a lower comparison base.

M&A Risk

E2 passes because intangibles actually declined 9% YoY — reflecting the held-for-sale reclassification and normal amortization. No new large acquisitions in FY2025.

Beneish M-Score

M-Score of -3.04 is notably clean — well below the -2.22 threshold. The clean DSRI (DSO improved 14 days) and the conservative accruals more than offset the SG&A pattern. Counterintuitive given the big-bath flag, but the M-Score is designed to detect earnings *inflation*, and Bio-Techne's FY2025 is the opposite — earnings were deflated by legitimate non-recurring charges.

Critical Audit Matter: Sufficiency of Audit Evidence Over Net Sales

KPMG identified one critical audit matter — and it is unusual. From the audit report:

"As discussed in Note 2 to the Company's consolidated financial statements, the Company recognizes revenue for sales of consumables and instruments at a point in time following the transfer of control of such products to the customer. The Company recorded $1,219.6 million of net sales for the year ended June 30, 2025. We identified the evaluation of the sufficiency of audit evidence over net sales as a critical audit matter. Evaluating the sufficiency of audit evidence obtained required especially subjective auditor judgment because of the dispersion of the Company's net sales generating activities across locations. This included determining the Company locations at which procedures were performed."

This is a site-coverage judgment: Bio-Techne operates across multiple global sites and KPMG had to decide which locations to test, and how deeply, to gather sufficient evidence about the aggregated revenue figure. Not a substantive revenue recognition concern.

KPMG's procedures included "software-assisted data analyses to test the relationships among certain sales transactions and... assessed the recorded net sales for a selection of transactions by comparing the amounts recognized for consistency with underlying documentation, including contracts with customers, shipping documentation, customer acceptance, and payments."

KPMG has served as Bio-Techne's auditor since 2002.

Key Risks from Item 1A

1. Research funding sensitivity. From Item 1A: "Our Protein Sciences segment products are sold primarily to research scientists at pharmaceutical and biotechnology companies and at university and government research institutions. Research and development spending by our customers and the availability of government research funding can fluctuate due to changes in available resources, mergers of pharmaceutical and biotechnology companies, spending priorities, general economic conditions and institutional and governmental budgetary policies."

2. Lab-developed test regulation. From Item 1A: "the U.S. government's... recently announced intention to regulate lab developed tests, may impact the customers and industries we serve by increasing the cost of commercializing and/or limiting the profitability of commercialized products."

3. Goodwill impairment exposure. From Item 1A: "We may be required to record a significant charge to earnings if our goodwill and other amortizable intangible assets or other investments become impaired." The FY2025 filing demonstrates the risk is live — $80.5M of held-for-sale impairment was recorded.

4. Wilson Wolf acquisition obligation. From Item 1A: "Bio-Techne also obtained a 19.9% ownership stake in Wilson Wolf and will acquire the remaining ownership no later than the end of calendar year 2027." This is a disclosed but not-yet-consummated future acquisition that will likely add material goodwill.

5. Acquisition integration risk. From Item 1A: "businesses, technologies, services and products that we acquire or invest in sometimes under-perform relative to our expectations and the price that we paid." The held-for-sale impairment implicitly acknowledges a past acquisition underperformance.

6. International exposure. From Item 1A: "approximately 44% of our sales revenue in fiscal 2025 coming from outside the U.S." Exposed to tariffs, FX, and Chinese policy changes.

Altman Z-Score and F-Score

Z-Score of 5.90 is comfortably in the safe zone — driven by strong gross margins and moderate leverage. The F-Score of 1.36 is slightly elevated, consistent with the accruals pattern around the impairments and litigation reserves.

Summary

Grade: F. Three fails including one critical (C4) and one big-bath signal (D4).

Bio-Techne's F grade is driven by three distinct issues:

D4 (write-off surge): This is the defining flag. Impairments of $80.5M (vs. $22.0M prior year) plus litigation charges of $41.8M (vs. $3.5M prior year) combined to create a $100M+ swing in non-recurring charges. The FY2025 GAAP net income of $73M is 56% below FY2024, while adjusted net income grew 8%. The "big bath" pattern is real in the data — next year's GAAP comparison will automatically look strong. Whether management orchestrated the pattern or whether these were legitimately triggered charges is a judgment call; the auditor (KPMG) issued an unqualified opinion.

C4 (cash vs. debt): Cash of $162M covers 37% of the $444M debt. Modest leverage in absolute terms (Debt/EBITDA 2.0x is a pass on D2).

D1 (goodwill + intangibles): At 70% of equity, reflects the cumulative acquisition history including Lunaphore, Advanced Cell Diagnostics, and the coming Wilson Wolf transaction.

The underlying operating business is healthy: 5% organic revenue growth, Protein Sciences at 75.6% gross margin, DSO improving 14 days, AR declining while revenue grows, and a clean M-Score of -3.04. The real questions for investors are: (1) how much of the FY2025 charges will recur vs. stay non-recurring, (2) how the Wilson Wolf acquisition (which closes by end of 2027) will be financed, and (3) whether the Protein Sciences growth reacceleration is sustainable.

**Disclaimer**: This report is based on Bio-Techne's FY2025 10-K (SEC EDGAR) and public financial data. This is NOT investment advice.

Data: SEC EDGAR 10-K (Fiscal year ended June 30, 2025) + Yahoo Finance

Auditor: KPMG LLP (Unqualified opinion, 1 critical audit matter: Sufficiency of audit evidence over net sales)